Analyst Price Target is $6.67
▲ +142.42% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Anebulo Pharmaceuticals in the last 3 months. The average price target is $6.67, with a high forecast of $8.00 and a low forecast of $6.00. The average price target represents a 142.42% upside from the last price of $2.75.
Current Consensus is
Buy
The current consensus among 3 investment analysts is to buy stock in Anebulo Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.
Read More